BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

NCT06773312 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: BC001+Sintilimab+XELOX

Sponsor

Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

Collaborators

[object Object]